253 related articles for article (PubMed ID: 12036831)
21. Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy and/or enzyme replacement therapy.
Kauli R; Zaizov R; Lazar L; Pertzelan A; Laron Z; Galatzer A; Phillip M; Yaniv Y; Cohen IJ
Isr Med Assoc J; 2000 Feb; 2(2):158-63. PubMed ID: 10804944
[TBL] [Abstract][Full Text] [Related]
22. [Analysis of the densitometric method of hand bone radiograms and assessment of early changes of bone structure in the children with Gaucher's disease on enzyme replacement therapy (ERT)].
Łyson-Wojciechowska G; Skawiński W; Tylki-Szymańska A
Pediatr Endocrinol Diabetes Metab; 2007; 13(4):218-223. PubMed ID: 18183671
[TBL] [Abstract][Full Text] [Related]
23. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1.
Andersson H; Kaplan P; Kacena K; Yee J
Pediatrics; 2008 Dec; 122(6):1182-90. PubMed ID: 19047232
[TBL] [Abstract][Full Text] [Related]
24. Enzyme replacement therapy with imiglucerase in a Taiwanese child with type 1 Gaucher disease.
Lin HY; Lin SP; Chuang CK; Wraith JE
J Chin Med Assoc; 2006 May; 69(5):228-32. PubMed ID: 16835986
[TBL] [Abstract][Full Text] [Related]
25. Skeletal involvement in Gaucher disease: An observational multicenter study of prognostic factors in the Argentine Gaucher disease patients.
Drelichman G; Fernández Escobar N; Basack N; Aversa L; Larroude MS; Aguilar G; Szlago M; Schenone A; Fynn A; Cuello MF; Aznar M; Fernández R; Ruiz A; Reichel P; Guelbert N; Robledo H; Watman N; Bolesina M; Elena G; Veber SE; Pujal G; Galván G; Chain JJ; Arizo A; Bietti J; Bar D; Dragosky M; Marquez M; Feldman L; Muller K; Zirone S; Buchovsky G; Lanza V; Sanabria A; Fernández I; Jaureguiberry R; Contte M; Barbieri María A; Maro A; Zárate G; Fernández G; Rapetti MC; Donato H; Degano A; Kantor G; Albina R; Á Lvarez Bollea M; Brun M; Bacciedoni V; Del Río F; Soberón B; Boido N; Schweri M; Borchichi S; Welsh V; Corrales M; Cedola A; Carvani A; Diez B; Richard L; Baduel C; Nuñez G; Colimodio R; Barazzutti L; Medici H; Meschengieser S; Damiani G; Nucifora M; Girardi B; Gómez S; Papucci M; Verón D; Quiroga L; Carro G; De Ambrosio P; Ferro J; Pujol M; Castella CC; Franco L; Nisnovich G; Veloso M; Pacheco I; Savarino M; Marino A; Saavedra JL
Am J Hematol; 2016 Oct; 91(10):E448-53. PubMed ID: 27420181
[TBL] [Abstract][Full Text] [Related]
26. Magnetic resonance imaging of bone marrow changes in Gaucher disease during enzyme replacement therapy: first German long-term results.
Poll LW; Koch JA; vom Dahl S; Willers R; Scherer A; Boerner D; Niederau C; Häussinger D; Mödder U
Skeletal Radiol; 2001 Sep; 30(9):496-503. PubMed ID: 11587517
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of treatment response to enzyme replacement therapy with Velaglucerase alfa in patients with Gaucher disease using whole-body magnetic resonance imaging.
Laudemann K; Moos L; Mengel E; Lollert A; Hoffmann C; Brixius-Huth M; Wagner D; Düber C; Staatz G
Blood Cells Mol Dis; 2016 Mar; 57():35-41. PubMed ID: 26852653
[TBL] [Abstract][Full Text] [Related]
28. Skeletal involvement in type 1 Gaucher disease: Not just bone mineral density.
Baldini M; Casirati G; Ulivieri FM; Cassinerio E; Khouri Chalouhi K; Poggiali E; Borin L; Burghignoli V; Cesana BM; Cappellini MD
Blood Cells Mol Dis; 2018 Feb; 68():148-152. PubMed ID: 28693786
[TBL] [Abstract][Full Text] [Related]
29. Enzyme replacement therapy with imiglucerase in Taiwanese patients with type I Gaucher disease.
Hsu CC; Chien YH; Lai MY; Hwu WL
J Formos Med Assoc; 2002 Sep; 101(9):627-31. PubMed ID: 12645190
[TBL] [Abstract][Full Text] [Related]
30. Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imiglucerase.
Smith L; Rhead W; Charrow J; Shankar SP; Bavdekar A; Longo N; Mardach R; Harmatz P; Hangartner T; Lee HM; Crombez E; Pastores GM
Mol Genet Metab; 2016 Feb; 117(2):164-71. PubMed ID: 26043810
[TBL] [Abstract][Full Text] [Related]
31. Decreased bone density in splenectomized Gaucher patients receiving enzyme replacement therapy.
Schiffmann R; Mankin H; Dambrosia JM; Xavier RJ; Kreps C; Hill SC; Barton NW; Rosenthal DI
Blood Cells Mol Dis; 2002; 28(2):288-96. PubMed ID: 12064924
[TBL] [Abstract][Full Text] [Related]
32. Cessation of enzyme replacement therapy in Gaucher disease.
Grinzaid KA; Geller E; Hanna SL; Elsas LJ
Genet Med; 2002; 4(6):427-33. PubMed ID: 12509713
[TBL] [Abstract][Full Text] [Related]
33. A Comprehensive Study of Bone Manifestations in Adult Gaucher Disease Type 1 Patients in Argentina.
Oliveri B; González D; Quiroga F; Silva C; Rozenfeld P
Calcif Tissue Int; 2019 Jun; 104(6):650-657. PubMed ID: 30790003
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic goals in Gaucher disease.
Mistry P; Germain DP
Rev Med Interne; 2006 Mar; 27 Suppl 1():S30-8. PubMed ID: 16644400
[TBL] [Abstract][Full Text] [Related]
35. [Enzyme replacement therapy for Gaucher paediatric disease: the only Tunisian experience].
Ben Turkia H; Azzouz H; Tebib N; Abdelmoula MS; Ben Chehida A; Hlel Y; Caillaud C; Sahli H; Ben Dridi MF
Tunis Med; 2009 May; 87(5):344-8. PubMed ID: 19927767
[TBL] [Abstract][Full Text] [Related]
36. Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis.
Mistry PK; Deegan P; Vellodi A; Cole JA; Yeh M; Weinreb NJ
Br J Haematol; 2009 Nov; 147(4):561-70. PubMed ID: 19732054
[TBL] [Abstract][Full Text] [Related]
37. Outcome of enzyme replacement therapy in Turkish patients with Gaucher disease: does late intervention affect the response?
Arikan-Ayyildiz Z; Yüce A; Emre S; Baysoy G; Saltik-Temizel IN; Gürakan F
Turk J Pediatr; 2011; 53(5):499-507. PubMed ID: 22272449
[TBL] [Abstract][Full Text] [Related]
38. The clinical course of untreated Gaucher disease in 22 patients over 10 years: hematological and skeletal manifestations.
Piran S; Roberts A; Patterson MA; Amato D
Blood Cells Mol Dis; 2009; 43(3):289-93. PubMed ID: 19793665
[TBL] [Abstract][Full Text] [Related]
39. Gaucher disease: unmet treatment needs.
Mehta A
Acta Paediatr; 2008 Apr; 97(457):83-7. PubMed ID: 18339195
[TBL] [Abstract][Full Text] [Related]
40. Baseline characteristics and outcome in Romanian patients with Gaucher disease type 1.
Grigorescu-Sido P; Drugan C; Alkhzouz C; Zimmermann A; Coldea C; Denes C; Grigorescu MD; Cret V; Bucerzan S
Eur J Intern Med; 2010 Apr; 21(2):104-13. PubMed ID: 20206881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
